DE3686622D1 - Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen. - Google Patents

Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.

Info

Publication number
DE3686622D1
DE3686622D1 DE8686306920T DE3686622T DE3686622D1 DE 3686622 D1 DE3686622 D1 DE 3686622D1 DE 8686306920 T DE8686306920 T DE 8686306920T DE 3686622 T DE3686622 T DE 3686622T DE 3686622 D1 DE3686622 D1 DE 3686622D1
Authority
DE
Germany
Prior art keywords
treatment
indolessic
hornically
bacteralians
anxietas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686306920T
Other languages
English (en)
Other versions
DE3686622T2 (de
Inventor
Maurice Ward Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858522455A external-priority patent/GB8522455D0/en
Priority claimed from GB868603910A external-priority patent/GB8603910D0/en
Priority claimed from GB868603909A external-priority patent/GB8603909D0/en
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of DE3686622D1 publication Critical patent/DE3686622D1/de
Publication of DE3686622T2 publication Critical patent/DE3686622T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE8686306920T 1985-09-11 1986-09-08 Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen. Expired - Fee Related DE3686622T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858522455A GB8522455D0 (en) 1985-09-11 1985-09-11 Anxiolytic compositions
GB868603910A GB8603910D0 (en) 1986-02-17 1986-02-17 Dioxopiperidine derivatives
GB868603909A GB8603909D0 (en) 1986-02-17 1986-02-17 Dioxopiperidine derivatives

Publications (2)

Publication Number Publication Date
DE3686622D1 true DE3686622D1 (de) 1992-10-08
DE3686622T2 DE3686622T2 (de) 1993-04-01

Family

ID=27262781

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8686306920T Expired - Fee Related DE3686622T2 (de) 1985-09-11 1986-09-08 Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE3650733T Expired - Fee Related DE3650733T2 (de) 1985-09-11 1986-09-08 Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3650733T Expired - Fee Related DE3650733T2 (de) 1985-09-11 1986-09-08 Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe

Country Status (8)

Country Link
US (4) US4738973A (de)
EP (2) EP0216555B1 (de)
JP (1) JPH0667839B2 (de)
AU (1) AU588365B2 (de)
CA (1) CA1273879A (de)
DE (2) DE3686622T2 (de)
DK (1) DK433786A (de)
GB (1) GB2181346B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263594B1 (de) * 1986-09-08 1992-06-24 Btg International Limited Dioxopiperidin-Derivate enthaltende anxiolytische Zusammensetzungen
GB2205745B (en) * 1987-06-16 1990-09-19 Nat Res Dev Use of dioxopiperidine derivatives as analgesics
GB8716337D0 (en) * 1987-07-10 1987-08-19 Nat Res Dev Antipsychotic compositions
GB8716338D0 (en) * 1987-07-10 1987-08-19 Nat Res Dev Anti-anxiogenic compositions
GB8826308D0 (en) * 1988-11-10 1988-12-14 Nat Res Dev Memory-enhancing compositions containing dioxopiperidine derivatives
US5177086A (en) * 1988-11-10 1993-01-05 National Research Development Corporation Memory-enhancing compositions containing dioxopiperidine derivatives
US4957915A (en) * 1989-02-27 1990-09-18 Biomeasure, Inc. Benzodiazepine analogs
US5104990A (en) * 1990-02-27 1992-04-14 G. D. Searle & Co. Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines
US5220019A (en) * 1990-02-27 1993-06-15 G. D. Searle & Co. Process for the preparation of diethyl 2-]2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1,1-dimethylpentyl]propandioate
JP2871811B2 (ja) * 1990-02-28 1999-03-17 サントリー株式会社 縮合７員環系化合物
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5089508A (en) * 1990-09-04 1992-02-18 Burzynski Stanislaw R Methods for treating aids
JP3481344B2 (ja) * 1995-04-19 2003-12-22 日本碍子株式会社 排ガス浄化用触媒の劣化検知方法及びそのためのシステム
JP3494508B2 (ja) 1995-06-26 2004-02-09 日本碍子株式会社 可燃性ガスセンサ、可燃性ガス濃度の測定方法及び触媒劣化検知方法
JP3708606B2 (ja) * 1995-12-15 2005-10-19 日本碍子株式会社 排気ガス浄化触媒の劣化検知方法
JP3830568B2 (ja) * 1995-12-18 2006-10-04 日本碍子株式会社 排気ガス浄化触媒の劣化検知方法
JP3761335B2 (ja) 1998-08-19 2006-03-29 トヨタ自動車株式会社 触媒劣化検出装置
DE19963903A1 (de) * 1999-12-31 2001-07-12 Bosch Gmbh Robert Verfahren zum Betreiben einer Brennkraftmaschine insbesondere eines Kraftfahrzeugs
DE10043124A1 (de) 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
GB2379216A (en) * 2001-08-28 2003-03-05 Maurice Ward Gittos Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders
GB0219639D0 (en) * 2002-08-22 2002-10-02 Prestwick Scient Capital Inc Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
EP3275885A1 (de) * 2016-07-28 2018-01-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthinderivate, deren verwendung als ein medikament und pharmazeutische zusammensetzungen damit
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE626279A (de) *
GB715755A (en) * 1950-07-07 1954-09-22 Ciba Ltd Manufacture of new diketopiperidines
GB1455687A (en) * 1972-12-28 1976-11-17 Aspro Nicholas Ltd Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
US4738973A (en) 1988-04-19
DK433786A (da) 1987-03-12
GB2181346B (en) 1989-10-04
EP0452765A2 (de) 1991-10-23
GB2181346A (en) 1987-04-23
EP0452765B1 (de) 1999-10-20
GB8621577D0 (en) 1986-10-15
DE3686622T2 (de) 1993-04-01
JPH0667839B2 (ja) 1994-08-31
US4835151A (en) 1989-05-30
JPS6261919A (ja) 1987-03-18
EP0216555B1 (de) 1992-09-02
CA1273879A (en) 1990-09-11
EP0216555A2 (de) 1987-04-01
DK433786D0 (da) 1986-09-10
AU6260186A (en) 1987-03-12
US4994475A (en) 1991-02-19
AU588365B2 (en) 1989-09-14
DE3650733D1 (de) 1999-11-25
EP0216555A3 (en) 1989-11-23
EP0452765A3 (en) 1992-06-10
DE3650733T2 (de) 2000-05-04
US4918084A (en) 1990-04-17

Similar Documents

Publication Publication Date Title
DE3686622D1 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
FI874671A (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE3688296D1 (de) Arzneimittel zur behandlung von erbrechen.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE3674246D1 (de) Behandlung von sauerem kohlenwasserstoffdestillat.
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3777861D1 (de) Behandlung von gasen.
DE3770184D1 (de) Behandlung von gasstroemen.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE3483330D1 (de) Mittel zur behandlung von erkrankungen der zahnwurzelhaut.
DE3670956D1 (de) Behandlung von fluessigkeiten.
DE3680881D1 (de) Behandlung von hologrammen.
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE3750071D1 (de) Methode zum Herabsetzen der Aktivität von Silicon-Polymeren.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
ATE135702T1 (de) Aryl- oder heteroaryl-1-alkyl-pyrrol-2- carbonsäure-derivate, zur behandlung von durch interleukin-1 hervorgerufenen erkrankungen
NO884635D0 (no) Fremgangsmaate for behandling av most.
DK160821C (da) 1,3-dihydro-4-benzoyl-2h-imidazol-2-oner samt middel til behandling af hjertesvigt
DK216687D0 (da) Fremgangsmaade til fremstilling af middel til be- handling af roeggas
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
DE3668338D1 (de) Kontinuierliche behandlung von spannungslosem gewebe.
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee